Status:
COMPLETED
Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors
Lead Sponsor:
Pfizer
Conditions:
Carcinoma
Eligibility:
All Genders
20-75 years
Phase:
PHASE1
Brief Summary
To evaluate the clinically recommended dose of AG-013736 (Axitinib) in Japanese patients by reviewing the safety of AG-013736 (Axitinib) following single and multiple dosing.
Eligibility Criteria
Inclusion
- Patients histologically or cytologically diagnosed with advanced malignant solid tumors
- Patients for whom standard therapies have not been effective, or for whom there are no suitable therapies
Exclusion
- Central lung lesions involving major blood vessels
- Patients who have been treated with bevacizumab or other VEGFR inhibitor(s)
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00447005
Start Date
February 1 2007
End Date
August 1 2009
Last Update
May 23 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Kashiwa, Chiba, Japan